Memory Pharmaceuticals Corp., a biopharmaceutical company, engages in the discovery and development of drug candidates for the treatment of central nervous system disorders in the United States. It offers drugs for neurological diseases associated with aging, such as Alzheimer’s disease, as well as certain psychiatric disorders, including schizophrenia, bipolar disorder, and depression. The company’s products for the treatment of Alzheimer’s disease comprise MEM 1414, a Phase I clinical stage product; MEM 1917, a preclinical completed product; and MEM 63908, a preclinical stage product. It is also developing MEM 3454, a Phase IIa product for the treatment of schizophrenia and/or Alzheimer’s disease; MEM 1003, a Phase IIa clinical stage product for the treatment of Alzheimer’s disease and bipolar disorder; and PDE10, a preclinical stage product for the treatment of neurological and psychiatric disorders. Memory Pharmaceuticals has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. for the development of its PDE4 inhibitors and nicotinic alpha-7 partial agonists; and Amgen, Inc. for the development of PDE10 inhibitors for neurological and psychiatric disorders. In addition, it has an agreement with The Stanley Medical Research Institute to develop MEM 1003 as a treatment for bipolar disorder. The company was founded in 1997 and is based in Montvale, New Jersey.